Author:
Müller Axel, ,Schweizer Johannes,Kirch Wilhelm,Schindler Christoph
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Alderman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. J Hypertens 1997;10:1–8.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–97.
3. Bergset J, Storozynsky E, Bisognano JD. Renin inhibition for hypertension: Selecting the right role for a new class of drug. Am J Ther:in press (Epub 2009 May 15).
4. Blumenstein M, Romaszko J, Calderon A, et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin 2009;25:903–10.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献